Search

Displaying results 5941 - 5950 of 8007 in total
  1. Drug

    AZD-2836

    go.drugbank.com/drugs/DB06031
    Investigational

    [A264853] The drug is being investigated for treatment of hepatitis C because AZD-2836 has in vitro anti-HCV activity.[A264858]

  2. Drug

    OPC1

    go.drugbank.com/drugs/DB17944
    Experimental

    OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.[L47082]

  3. Drug

    PMC-403

    go.drugbank.com/drugs/DB18132
    Investigational

    PMC-403 is a novel Tie2-activating antibody being investigated for the treatment of systemic capillary leak syndrome.

  4. Drug

    Prosetin

    go.drugbank.com/drugs/DB18649
    Investigational

    Prosetin is an orally administered blocker of MAP4K under investigation for the treatment of amyotrophic lateral sclerosis.[L48360]

  5. Drug

    Rovaleucel

    go.drugbank.com/drugs/DB18691
    Investigational

    Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.

  6. Drug

    Abiprubart

    go.drugbank.com/drugs/DB19333
    Investigational

    Abiprubart is being evaluated for its efficacy and safety in participants with Sjögren's Disease in clinical trial NCT06531395

  7. Drug

    Agerafenib

    go.drugbank.com/drugs/DB15068
    Investigational

    Agerafenib is under investigation in clinical trial NCT03052569 (Expanded Access to RXDX-105 for Cancers With RET Alterations).

  8. Drug

    Ibezapolstat

    go.drugbank.com/drugs/DB16189
    Investigational

    Ibezapolstat is under investigation in clinical trial NCT04247542 (ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection).

  9. Drug

    Brilacidin

    go.drugbank.com/drugs/DB12997
    Investigational

    Brilacidin is under investigation for the supportive care of Mucositis, Stomatitis, Mouth Diseases, and Head and Neck Neoplasms.

  10. Drug

    Setipiprant

    go.drugbank.com/drugs/DB12562
    Investigational

    Setipiprant has been investigated for the treatment of Seasonal Allergic Rhinitis, asthma and scalp hair loss (Androgenetic Alopecia).